Literature DB >> 35797920

Harnessing IgG Fc glycosylation for clinical benefit.

Eva J Archer1, Joseph C Gonzalez2, Debopam Ghosh3, Elizabeth D Mellins3, Taia T Wang4.   

Abstract

The effector activity of IgG antibodies is regulated at several levels, including IgG subclass, modifications of the Fc glycan, and the distribution of Type I and II Fcγ receptors (FcγR) on effector cells. Here, we explore how Fc glycosylation, particularly sialylation and fucosylation, tunes cellular responses to immune complexes. We review the current understanding of the pathways and mechanisms underlying this biology, address FcγR in antigen presentation, and discuss aspects of the clinical understanding of Fc glycans in therapies and disease.
Copyright © 2022. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35797920     DOI: 10.1016/j.coi.2022.102231

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.268


  1 in total

1.  Editorial: Glycotherapeutics: Design, synthesis, function and biomedical application of agents emerging from glycochemistry and glycobiology.

Authors:  M Osman Sheikh; Chantelle J Capicciotti; Stéphanie Olivier-Van Stichelen
Journal:  Front Mol Biosci       Date:  2022-09-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.